HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive: Because epigenetic alterations may be controlled, novel medications that target distinct epigenetic pathways, such as demethylating agents and HDAC inhibitors, have been evaluated for CML treatment, particularly in individuals who have developed imatinib resistance.